Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy

Transplant International

Volumn 17, Issue 3, 2004, Pages 120-125

  Filler, Guido ^a  

^a CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

Area under the curve; Children; Mycophenolate mofetil; Mycophenolic acid; Pharmacokinetics; Tacrolimus

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PRODRUG; TACROLIMUS;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; ORGAN TRANSPLANTATION; PEDIATRIC SURGERY; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 2442712496     PISSN: 09340874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00147-003-0678-z     Document Type: Article

References (19)

1. Jensen CW, Jordan ML, Schneck FX, et al. Pediatric renal transplantation under FK 506 immunosuppression. Transplant Proc 1991; 23:3075.
2. Woude FJ van der. Mycophenolate mofetil (RS 61443): nothing new under the sun or an important break-through in the field of transplantation? Nephrol Dial Transplant 1995; 10:1112.
3. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 1993; 136:5.
4. Filler G, Grygas R, Mai I, et al. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant 1997; 12:1668.
5. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345:1321.
6. Ettenger R, Menster B, Warshaw B, Potter D, Nichols A. Mycophenolate mofetil (MMF) in pediatric (ped) renal transplantation (TX): final report of the pediatric MMF study group (PMMFSG). 16th Annual Meeting of the American Society of Transplant Physicians, 1997: abstract 287.
7. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998; 9:1511.
8. Jacqz-Aigrain E, Khan-Shaghaghi E, Baudouin V, et al. Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. Pediatr Nephrol 2000; 14:95.
9. Filler G, Lampe D, Mai I, Strehlau J, Ehrich JHH. Reduced dosing of MMF in combination with tacrolimus for steroid-resistant, vascular rejection in renal allografts. Transpl Int 1998; 11 (Suppl 1): 82.
10. Zucker K, Rosen A, Tsaroucha A, et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. Transpl Immunol 1997; 5:225.
11. Cox VC, Ensom MH. Mycophenolate mofetil for solid organ transplantation: does the evidence support the need for clinical pharmacokinetic monitoring? Ther Drug Monit 2003; 25:137.
12. Shaw LM, Kaplan B, Kaufman D. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. Clin Chem 1996:42; 1316.
13. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 2000; 22:169.
14. Filler G, Feber J, Lepage N, Weiler G, Mai I. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant 2002; 6:411.
15. Shaw LM, Holt DW, Keown P, Venkataramanan R, Yatscoff RW. Current opinions on therapeutic drug monitoring of immunosuppressive drugs. Clin Ther 1999; 10:1632.
16. Schütz E, Shipkova M, Armstrong VW, et al. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 1998; 30:1185.
17. Krouwer JS, Monti KL. A simple, graphical method to evaluate laboratory assays. Eur J Clin Chem Clin Biochem 1995; 33:525.
18. Pawinski T, Hale M, Korecka M, Fitzsimmons WE, Shaw LM. Limited sampling strategy for the estimation of mycophenolic acid area under the curve in adult renal transplant patients treated with concomitant tacrolimus. Clin Chem 2002; 48:1497.
19. Langman LJ, LeGatt DF, Halloran PF, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression in renal transplant recipients. Transplantation 1996; 62:666.